These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39078681)

  • 1. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.
    Mühlemann B; Trimpert J; Walper F; Schmidt ML; Jansen J; Schroeder S; Jeworowski LM; Beheim-Schwarzbach J; Bleicker T; Niemeyer D; Richter A; Adler JM; Vidal RM; Langner C; Vladimirova D; Wilks SH; Smith DJ; Voß M; Paltzow L; Martínez Christophersen C; Rose R; Krumbholz A; Jones TC; Corman VM; Drosten C
    Proc Natl Acad Sci U S A; 2024 Aug; 121(32):e2310917121. PubMed ID: 39078681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of prior immunity in binding to spike of "future" Omicron subvariants.
    Biswas D; Mahalingam G; Subaschandrabose RK; Priya S; Ramachandran R; Suresh S; Mathivanan TV; Balu NV; Selvaraj K; Nellickal AJ; Christudoss P; Samuel P; Kt RD; Marepally S; Moorthy M
    Indian J Med Microbiol; 2024; 50():100615. PubMed ID: 38782260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
    Mykytyn AZ; Rissmann M; Kok A; Rosu ME; Schipper D; Breugem TI; van den Doel PB; Chandler F; Bestebroer T; de Wit M; van Royen ME; Molenkamp R; Oude Munnink BB; de Vries RD; GeurtsvanKessel C; Smith DJ; Koopmans MPG; Rockx B; Lamers MM; Fouchier RAM; Haagmans BL
    Sci Immunol; 2022 Sep; 7(75):eabq4450. PubMed ID: 35737747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
    Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani HH; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
    J Virol; 2023 Sep; 97(9):e0062823. PubMed ID: 37676002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
    van der Straten K; Guerra D; van Gils MJ; Bontjer I; Caniels TG; van Willigen HDG; Wynberg E; Poniman M; Burger JA; Bouhuijs JH; van Rijswijk J; Olijhoek W; Liesdek MH; Lavell AHA; Appelman B; Sikkens JJ; Bomers MK; Han AX; Nichols BE; Prins M; Vennema H; Reusken C; de Jong MD; de Bree GJ; Russell CA; Eggink D; Sanders RW
    Immunity; 2022 Sep; 55(9):1725-1731.e4. PubMed ID: 35973428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
    Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
    Wang W; Lusvarghi S; Subramanian R; Epsi NJ; Wang R; Goguet E; Fries AC; Echegaray F; Vassell R; Coggins SA; Richard SA; Lindholm DA; Mende K; Ewers EC; Larson DT; Colombo RE; Colombo CJ; Joseph JO; Rozman JS; Smith A; Lalani T; Berjohn CM; Maves RC; Jones MU; Mody R; Huprikar N; Livezey J; Saunders D; Hollis-Perry M; Wang G; Ganesan A; Simons MP; Broder CC; Tribble DR; Laing ED; Agan BK; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    Cell Host Microbe; 2022 Dec; 30(12):1745-1758.e7. PubMed ID: 36356586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters.
    Yang ZH; Song YL; Pei J; Li SZ; Liu RL; Xiong Y; Wu J; Liu YL; Fan HF; Wu JH; Wang ZJ; Guo J; Meng SL; Chen XQ; Lu J; Shen S
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
    Wang Q; Guo Y; Iketani S; Nair MS; Li Z; Mohri H; Wang M; Yu J; Bowen AD; Chang JY; Shah JG; Nguyen N; Chen Z; Meyers K; Yin MT; Sobieszczyk ME; Sheng Z; Huang Y; Liu L; Ho DD
    Nature; 2022 Aug; 608(7923):603-608. PubMed ID: 35790190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.